Announcement
Copy of Newspaper Publication 1 Sep - Mixed newspaper articles; no clear Sheel Biotech announcement.
Source: Nse
Sheel Biotech Ltd. (SHEEL)
SME CapPharma stocks · SME cap · NSE
Sheel Biotech Ltd. operates in Biotech Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 04:50 pm ISTDetails
Quote19 Oct, 04:50 pm IST
Base fundamentals03 Oct 2026 · screener
Latest result26 Apr, 11:29 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
72BullishSMA20 -6.1% / mo · MACD + · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 54
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SHEELD candles · FIT view+43.0%Latest close ₹62.50 on 2026-10-15
Bar
+0.6%
RSI
52
MACD hist
0.21
52W pos
51%
2026-10-15O ₹62.15H ₹62.50L ₹62.15C ₹62.50Vol 16,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SHEELNifty PharmaNifty 500
- SHEEL
- -13.2%
- Nifty 500
- -4.7%
- Nifty Pharma
- -0.8%
- Vs Nifty 500
- -8.5 pp
Chart stats
15 Oct 2026- From 52W high
- -34.6%
- 52W range position
- 43%
- ATR (14)
- 3.6%
- Volume vs 20D
- 1.14x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹57 - ₹63.3
₹95.6
₹37.8 - ₹95.6
₹2.3
Latest completed session
20-session average
49.6% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED60
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish72
Price trend and sector-relative-strength timing.
Valuation
Legacy model+76.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence67
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Sept 2025
Pending dataYoY comparison unavailable - result verdict pending data
Filed 30 Sept 2025
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹22 Cr | NDF | +100.0% |
| EBITDA | ₹2 Cr | NDF | NDF |
| Operating margin | 8.0% | NDF | NDF |
| PAT | ₹0 Cr | NDF | NDF |
| PAT margin | 0.0% | NDF | NDF |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 10.40
- P/B
- 0.96
- EV/EBITDA
- 7.76
- Market Cap
- 123.00Cr
Profitability
- ROE
- 11.20%
- ROCE
- 13.50%
- ROA
- 8.22%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 12.00%
- EPS 5Y
- 20.00%
- Revenue 3Y
- 7.00%
- EPS 3Y
- 32.00%
Balance Sheet
- Debt/Equity
- 0.07
- Interest Coverage
- 8.00×
- Altman Z
- 6.34
- Book Value
- 62.40
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- -18.00 Cr
- EPS TTM
- 5.78
Shareholding
- Promoter Hold
- 72.29%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 39%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 22.0+100.0% vs prev
Net Profit
₹ CrLatest: 0.0+100.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 52. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~6.5% over last month) — short-term momentum negative.
- RSI(14) at 52 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 28% off 52W high · 65% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
72
RS percentile
Stage 1 Base / Transition
1M return
+1.5%
3M return
-0.8%
6M return
+14.1%
1Y return
-
RS 1D
+5
RS 20D
+11
Sector rank
#1
Industry rank
#65
Stage evidence
- Price is 10.2% above the 30-week proxy without full trend alignment.
- The 30-week proxy changed -1.7% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
improving
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
221 observations
15 Oct 2026Value 68.15+4.28%
RS vs Nifty 50068
Valuation & peers
U-Score 60 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 60 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation27/30
Growth22/25
Quality2/20
Balance Sheet13/15
Cash Flow1/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
60
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
60/100 · legacy band UNDERVALUED
Positive drivers
- Fair-value margin of safety is positive at 76.0%.
- Valuation contributes 27/30 to the score.
- Growth contributes 22/25 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
10.4
PB
1.0
EV/EBITDA
7.8
ROE
11.2%
ROCE
13.5%
FCF Yield
—
Debt/Equity
0.1
MoS
+76.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
60
Previous: 60
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+76.0%
Previous: +76.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
60
60
60
60
60
60
60
60
60
60
60
60
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹90.08
+30.6% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹260.1
+76.0% MoS
PEG
0.42
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INDOUS
Small
Indo Us Biotech Limited
Biotechnology
match 130
42
29.9
16.9%
+43%
WATCHLIST
AJOONI
Small
Ajooni Biotech Limited
Biotechnology
match 128
56
13.5
4.3%
+72%
FAIR VALUE
NATHBIOGEN
Small
Nath Bio-Genes (India) Limited
Biotechnology
match 121
35
7.7
5.3%
-124%
WATCHLIST
HESTERBIO
Small
Hester Biosciences Limited
Biotechnology
match 116
57
33.7
15.9%
+28%
FAIR VALUE
BIOCON
Mid
Biocon Limited
Biotechnology
match 114
32
78.9
1.4%
-2833%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Sheel Biotech Ltd. operates in Biotech Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Sept 2025. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
67Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 39th percentile within Pharma. Main check: cash conversion is weak at 40/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
1 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
52nd percentile
overall median 67 · Pharma: 39th pctile, median 70 · SME: 66th pctile, median 64
Evidence depth
Financial-only
1 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
40
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 72.3%.
- ▸Promoter pledge is zero.
Trust risks
- ▸Operating cash flow is negative at ₹-18 Cr.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Sheel Biotech Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentation
Updates 14 Jul - FY26 investor presentation highlights ₹110 Cr+ revenue, 1.5 crore plant capacity, and 1,98,502 farmers.
Source: Nse
Annual report
Annual Report 2026
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.